marked.bio

Company

Xuanzhu Biopharmaceutical

2 active trials that select patients by a biomarker on marked.bio, across 3 biomarkers.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Trials

2 of 5 trials shown

  1. A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors

    Recruiting Phase 1/2 Xuanzhu Biopharmaceutical Started 2021Primary completion 2025-09 NCT04996121

    XZP-5955 tablets

    Priority will be given to patients who have previously documented NTRK or ROS1 gene fusion confirmed by the central laboratory

    ROS1 fusionNTRK1/2/3 fusionStatus may be outdated, last updated 2022-08-30Locally Advanced or Metastatic Solid Tumors, Locally Advanced or Metastatic Non-small Cell Lung Cancer

  2. A Study of KM501 in Patients With Solid Tumors

    Not yet recruiting Phase 1 Xuanzhu Biopharmaceutical Started 2023Primary completion 2026-12 NCT05804864

    KM501

    Advanced non-small cell lung cancer with a HER2 mutation.

    HER2 (ERBB2) activating mutationStatus may be outdated, last updated 2023-04-07Advanced Solid Tumors